Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2849330 PET Imaging in Advanced HER3+ Solid Tumors
NCT02345174Phase 1Completed
- Sponsor
- GSK
- Start
- Mar 2015
- Primary completion
- Jun 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GSK2849330 in solid tumor, sponsored by GSK. Primary endpoints: Standardized Uptake Value and Volume of region of interest. Started Mar 2015; status: completed.
02
Drugs
GSK2849330
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02345174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02345174.